

Local Anesthetics Have a Major Impact on Viability of Preadipocytes and Their Differentiation into Adipocytes

Maike Keck, M.D.
Maximilian Zeyda, Ph.D.
Karina Gollinger
Sonja Burjak
Lars-Peter Kamolz, Ph.D.
Manfred Frey, Ph.D.
Thomas M. Stulnig, Ph.D.

Vienna, Austria

Background: Autologous fat transplantation is a well-established technique in surgery. Moreover, the use of preadipocytes in soft-tissue engineering is currently being intensely investigated. Current efforts focus on identifying maneuvers that may minimize resorption and provide predictable late results. The aim of this study was to investigate the influence of different local anesthetics frequently used in clinical practice on the viability of preadipocytes and their ability to differentiate into adipocytes.

Methods: Human preadipocytes were isolated from subcutaneous adipose tissue of 15 patients and treated with bupivacaine, mepivacaine, ropivacaine, articaine/epinephrine, and lidocaine for 30 minutes. Viability was determined directly after treatment and during the ensuing cultivation. Differentiation of preadipocytes was determined by expression of the adipocyte marker adiponectin.

Results: Although the immediate effects of mepivacaine and ropivacaine were only moderate, treatment with articaine/epinephrine and lidocaine strongly impaired preadipocyte viability. Cells normally attached to the culture dishes and proliferated irrespective of the previous treatment. During long-term cultivation, articaine/epinephrine-treated cell viability decreased markedly, whereas other local anesthetics had no impact. Despite normal phenotypic appearance of cells treated with bupivacaine, mepivacaine, ropivacaine, and lidocaine, all local anesthetics markedly impaired adipocyte differentiation as determined by adiponectin expression.

Conclusions: The authors' results show that there is a marked influence of local anesthetics not only on the quantity but also on the quality of viable preadipocytes as determined by their ability to differentiate into mature adipocytes. Therefore, these results should be considered in the context of autologous fat transfer and soft-tissue engineering. (*Plast. Reconstr. Surg.* 126: 1500, 2010.)

Autologous fat transplantation with lipoinjection for soft-tissue augmentation is a commonly used surgical technique. Adipose tissue grafts have been used for soft-tissue augmentation in a diverse range of surgical procedures for more than 100 years.¹⁻⁴ Current efforts focus on identifying maneuvers that may minimize resorption and provide predictable late results. The most important problem of this method is the yet unpredictable resorption rate of the transplanted tissue. Explantation of adipose tissue as

performed during the procedure of autologous fat transfer confers stress to preadipocytes and adipocytes. Disruption of blood supply during fat harvesting may result in hypoxia and apoptosis of the heterogeneous population of cells present in adipose tissue.⁵⁻⁸ This may explain why a mean resorption rate of only 40 to 50 percent is described, and some studies also report approximately only 10 percent viable cells in the transplant.⁹⁻¹³

Preadipocytes play an important role in soft-tissue augmentation,¹⁴ because these adipocyte precursor cells have a higher survival rate under ischemic conditions than mature adipocytes and even have the ability to proliferate and differentiate into

From the Division of Plastic and Reconstructive Surgery, Department of Surgery, and the Clinical Division of Endocrinology and Metabolism, Department of Medicine III, Medical University Vienna.

Received for publication March 1, 2010; accepted May 3, 2010.

Copyright ©2010 by the American Society of Plastic Surgeons

DOI: 10.1097/PRS.0b013e3181ef8beb

Disclosure: *The authors have no financial interest to declare in relation to the content of this article.*

mature adipocytes after transplantation.^{15–17} Moreover, they are used for in vivo and in vitro tissue engineering.¹⁸ Research in tissue engineering has developed rapidly over the past several years and offers alternative strategies for soft-tissue augmentation, which might be superior to traditional surgical options. The conventional reparative approach is replaced by a regenerative approach.

Because of their key role in autologous fat transfer^{19,20} and soft-tissue augmentation, we focused our examinations on preadipocytes to evaluate the impact of local anesthetic treatment on the quantity and quality of preadipocytes yielded from adipose tissue grafts. In a previous work, we have shown that incubation of preadipocytes with lidocaine and articaine plus epinephrine caused a significant reduction of cell viability by immediate necrotic effects.²¹ In this study, we chose local anesthetics according to their frequent use in clinical practice and investigated their effects beyond immediate reduction of cell viability. Therefore, we determined the ability of treated preadipocytes to grow and differentiate into adipocytes.

MATERIALS AND METHODS

Subcutaneous adipose tissue was obtained from 15 healthy patients undergoing reductional plastic surgery. This study was approved by the ethics committee of the Medical University of Vienna and the General Hospital Vienna (EK no. 275/2006). All subjects gave written informed consent before taking part in the study.

Isolation of Preadipocytes and Local Anesthetic Treatment

Minced adipose tissue was washed in phosphate-buffered saline and digested with 2 mg/ml collagenase type IV in Hanks' buffered salt solution (both obtained from Sigma Chemical Co., St. Louis, Mo.), 0.01 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid supplemented with 50 μ g/ml streptomycin, 50 U/ml penicillin (both from Invitrogen, Carlsbad, Calif.), and 25 μ g/ml amphotericin B (Sigma) for 1 hour at 37°C with constant shaking. Cells were filtered through a 250- μ m nylon filter and centrifuged for 10 minutes at 380 g. Red blood cells were lysed in hypotonic buffer, cells were centrifuged for 10 minutes at 380 g, and cell pellets were resuspended in Dulbecco's Modified Eagle Medium/Ham's F12 (Sigma), supplemented with 14 mM/liter sodium bicarbonate, 16.5 mM/liter biotin, 8.5 mM/liter pantothenate, 15 mM/liter glucose, 13.5 mM/liter 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (all Sigma), 2 mM/liter L-glutamine, 200 μ g/ml

kanamycin, 100 units/ml penicillin, 100 μ g/ml streptomycin (all from Invitrogen), and 10% fetal calf serum (HyClone; Thermo Scientific, Logan, Utah). After filtration through a 70- μ m nylon mesh, cells were dispensed under constant stirring onto six-well plates and incubated at 37°C in a humidified atmosphere with 5% carbon dioxide for 24 to 48 hours. Subsequently, nonadherent cells were removed by washing with phosphate-buffered saline, adherent cells trypsinized and, after washing/centrifugation, resuspended in 1% bupivacaine, 1% mepivacaine, 0.5% ropivacaine, 4% articaine plus epinephrine 1:100,000, and 2% lidocaine or physiologic saline solution as control for 30 minutes at room temperature. After another washing step, viability was quantified by propidium iodide exclusion using a fluorescence-activated cell sorter (FACS-Canto; BD Biosciences, San Jose, Calif.). Viability after local anesthetic treatment was compared with that after saline control treatment (88.2 ± 1.9 percent propidium iodide-negative cells), which was taken as 100 percent.

Adipocyte Differentiation

A specific feature of mature adipocytes is expression of adiponectin (*ADIPOQ* gene).²² To assess local anesthetic on adipocyte maturation, preadipocytes were reincubated at equal viable cell densities (50,000 cells/cm²) in the same culture medium as before for 4 days for proliferation. To induce adipocyte differentiation, cells were incubated for 12 days in Dulbecco's Modified Eagle Medium/Ham's F12, 33 μ M biotin, 17 μ M pantothenate, 1 nM triiodothyronine, 100 nM dexamethasone (all from Sigma), 500 nM human insulin (Roche, Basel, Switzerland), 1 μ M rosiglitazone (generously provided by Johnson & Johnson, New Brunswick, N.J.), and, for the first 3 days, 250 μ M IBMX (Sigma).

Subsequently, total RNA was prepared from five samples by homogenizing cells in Trizol reagent (Invitrogen) followed by RNA extraction according to the manufacturer's instructions. RNA was transcribed into cDNA by Superscript II using random hexamer priming (Invitrogen). Quantitative real-time polymerase chain reaction was performed using an adiponectin-specific commercial Assay-on-Demand (Applied Biosystems, Foster City, Calif.) normalized to ubiquitin C expression as endogenous control (Applied Biosystems). Expression of specific mRNA in each sample was quantitated in duplicates on an ABI PRISM 7000 Cyclor (Applied Biosystems) using the $\Delta\Delta C_T$ method.




Fig. 1. Viability of preadipocytes after treatment with local anesthetics. Viability was assessed by flow cytometry immediately after treatment with indicated local anesthetics. The diagram shows cell viability in mean \pm SEM, with the saline control treatment taken as 100 percent ($n = 15$). Significant differences from control are indicated by asterisks: * $p < 0.05$; *** $p < 0.001$.

Statistical Analysis

Data are expressed as means \pm SEM. Univariate analysis of variance followed by Dunnett post hoc testing was calculated.

RESULTS

Effects of Local Anesthetic on Preadipocyte Viability

With the exception of bupivacaine, all local anesthetics significantly reduced cell viability, but to differing extents, as determined directly after treatment and compared with saline control treatment (Fig. 1). Although the effects of mepivacaine and ropivacaine were relatively moderate, treatment with articaine/epinephrine and lidocaine left only 32 ± 9 percent and 61 ± 6 percent of preadipocytes viable, respectively. As demonstrated in Figure 2, above, showing similar cell densities on day 5 of induced cell differentiation, cells normally attached to the culture dishes and proliferated irrespective of the previous treatment when seeded at identical viable cell numbers per well. Interestingly, during long-term cultivation, articaine/epinephrine-treated cell viability markedly decreased as determined by reduced cell density, small size, and round shape indicating apoptosis (Fig. 2, below), whereas bupivacaine, ropivacaine (not shown), mepivacaine, and lidocaine (Fig. 2, below) had no impact on viability also




Fig. 2. Effects of local anesthetics on preadipocyte culture and differentiation. After local anesthetic and control (physiologic saline solution) treatment, cells were seeded at the same viable cell densities, cultivated, and induced to differentiate into adipocytes as described in the Materials and Methods section. Images show typical examples of cells treated as indicated on days 5 (above) and 12 (below) after induction of differentiation are shown.

on day 12 of the differentiation process compared with control treatment.

Effects of Local Anesthetics on Adipocyte Differentiation

In addition to these quantitative analyses, we investigated the effects of local anesthetics on the quality of preadipocytes as assessed by their ability to differentiate into adipocytes. Irrespective of pretreatment, cells started to form lipid droplets on day 5 after induction of differentiation (Fig. 2, *above*). Also, at the end of the differentiation process, no differences in cell size or lipid droplet formation were detectable between control and local anesthetic-treated cells (Fig. 2, *below*; data not shown), with the exception of articaine/epinephrine-treated cells that were markedly smaller while a similar percentage of these cells were loaded with lipid droplets (Fig. 2, *below*). Despite this normal phenotypical appearance of cells treated with bupivacaine, mepivacaine, ropivacaine, and lidocaine, all local anesthetics markedly affected adipocyte differentiation as determined by their expression of the differentiation marker adiponectin (Fig. 3). The strongest impairment of adiponectin expression was observed after lidocaine treatment (Fig. 3).

DISCUSSION

A high number of patients suffer from disfiguring loss of soft tissue because of posttraumatic defects, tumor defects, or congenital deformities. Thus, successful long-term treatment of soft-tissue defects remains a desirable goal. One possibility for correcting some of these defects is autologous fat transplantation. A major challenge of this method is predicting the resorption rate of the transplanted tissue to determine the exact amount of fat that needs to be transplanted. In clinical practice, not much is known about the survival rates of the transplanted fat cells. Several studies have been conducted to demonstrate that specimen handling, type of canula, body region aspirated, and anatomical characteristics of patients all affect the degree of resorption of the transplanted fat graft from liposuction aspirate.^{5,6,8,23,24} Overall, the fewer traumas that occurred during harvesting, handling, and transplantation, the more consistent the volume that was maintained in the long term.⁹ Our results implicate that the use and the choice of local anesthetics has to be considered as well.

Cytotoxicity of local anesthetics on different cell types including neurons has been the subject




Fig. 3. Adiponectin expression of preadipocytes after treatment with local anesthetics. After treatment with indicated local anesthetics, preadipocytes were differentiated into adipocytes for 12 days. Adiponectin mRNA expression was assessed by quantitative real-time reverse-transcriptase polymerase chain reaction and normalized to ubiquitin C expression. The diagram shows mean \pm SEM of adiponectin expression with the saline control treatment taken as 100 percent ($n = 5$). Significant differences from control are indicated by asterisks: * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.

of several studies.^{25–29} Recently, toxic actions of local anesthetics have been shown to correlate with their lipophilic properties.^{30,31} However, our results suggest the effects on preadipocyte viability and differentiation to be independent of lipophilic properties, because ropivacaine is less lipophilic than bupivacaine but affects preadipocytes more than bupivacaine. All local anesthetics used in the present study are members of the amide family. Articaine, which in combination with epinephrine shows particularly strong adverse effects in our study, is exceptional because it contains an additional ester group that is metabolized by esterases in blood and tissue,³² but whether this chemical property is related to the effects shown here remains unclear. Thus, it needs to be elucidated in future studies which of several molecular and cellular mechanisms that have been described for local anesthetics, such as induction of apoptosis,^{33,34} induction of calcium flux,³⁵ activation of signaling kinases, and inhibition of the energy production in the mitochondria,^{36–41} are responsible for the effects described here.

Local anesthetic effects on adipose tissue have been the subject of previous studies as well. Shoshani and colleagues investigated the influence of lidocaine and adrenaline on the viability of injected adipose tissue in nude mice. No influence of lidocaine and adrenaline could be detected.⁴² The reasons for the apparent difference of the results of this murine study from our in vitro results have to be investigated. However, the present study corroborates earlier data showing that lidocaine and articaine plus epinephrine causes a significant reduction of preadipocyte viability by immediate necrotic effects,²¹ extending these observations not only to different local anesthetics but, importantly, to preadipocyte growth and development, putatively important issues that have been neglected so far.

For successful autologous fat transfer, differentiation of the transplanted preadipocytes into adipocytes may be of particular importance.^{19,20,43,44} Moreover, preadipocytes have become the focus of research on soft-tissue engineering. Preadipocytes can be expanded in vitro and implanted directly⁴⁵ or onto three-dimensional scaffolds.^{16–18,46} Therefore, both the quantity of adipocytes surviving the transplantation or isolation and also the ability of preadipocytes to differentiate are of importance when evaluating the procedure of choice to gain adipose tissue with high resorption rate or viable and functional preadipocytes, including the use of local anesthetics.

In a previous study, we showed that 1% lidocaine, 0.5% ropivacaine, and 4% articaine plus epinephrine impaired preadipocyte viability. Here, we extended the study to bupivacaine, mepivacaine, and 2% lidocaine. Furthermore, we investigated the influence on the ability of preadipocytes to differentiate as determined by their ability to express adiponectin, an adipokine with multiple beneficial local and systemic functions.⁴⁷

Most surgeons wait for approximately 30 minutes after tumescence for the infiltration fluid to percolate properly and for its full pharmacologic effects to occur.⁴⁸ In our in vitro setting, cells were incubated with the substances for 30 minutes, corresponding approximately to the time of exposure during fat transplantation. The immediate harvest of fat after injection of local anesthetics as practiced by some surgeons could be favorable for limiting exposure time and avoiding the adverse effects as described here. The substances were applied in the same concentrations as those used for infiltration in clinical practice, but resulting in vivo concentrations may be different because of dilution effects which, however, are difficult to estimate. Therefore, confirmation of our results

and assessment of their in vivo relevance in clinical studies are topics of great interest.

The results of our in vitro research presented here are intended to improve the overall reliability of the harvest of fat grafts by allowing the surgeon to avoid adverse effects of distinct local anesthetics. Our data indicate that 4% articaine with epinephrine and 2% lidocaine may be inappropriate for these purposes. Furthermore, although the effects of bupivacaine, mepivacaine, and ropivacaine on viability are relatively moderate, the impairment of adipocyte differentiation by treatment with these substances provokes a reconsideration of the use of local anesthesia in general. Reduced levels of adiponectin alone could have serious consequences on the function of reconstituted adipose tissue.⁴⁹ However, whether and how reduced expression of adiponectin in normally appearing adipocytes affects autologous fat transfer and soft-tissue engineering remains to be elucidated in conjunction with functional defects of adipocytes derived from anesthetic-treated preadipocytes. In any case, alternatives such as the use of tumescent solution or other anesthetic procedures should be considered.

Altogether, our results show that distinct local anesthetics affect preadipocyte viability to greatly varying degrees, although all local anesthetics investigated here significantly impaired the ability of preadipocytes to differentiate into adipocytes. This could be of major importance in the context of autologous fat transfer and soft-tissue engineering, because the choice of the right local anesthesia for infiltrating the donor site could influence the clinical outcome. We urge that further studies be conducted to evaluate the clinical relevance of our findings.

Maike Keck, M.D.

Department of Plastic and Reconstructive Surgery
Medical University Vienna
Währingergürtel 18–22
1070 Vienna, Austria
maike.keck@meduniwien.ac.at

REFERENCES

1. Neuber F. Fetttransplantation. *Zentralbl Chir.* 1893;22:66.
2. Coleman SR. Long term survival of fat transplants: Controlled demonstrations. *Aesthetic Plast Surg.* 1995;9:421–425.
3. Coleman SR. Facial recontouring with liposuction. *Clin Plast Surg.* 1997;24:347–367.
4. Glashofer M, Lawrence N. Fat transplantation for treatment of the senescent face. *Dermatol Ther.* 2006;19:169–176.
5. Carpaneda CA. Study of aspirated adipose tissue. *Aesthetic Plast Surg.* 1996;20:399–402.
6. Chajchir A, Benzaquen I. Fat-grafting injection for soft tissue augmentation. *Plast Reconstr Surg.* 1989;84:921–934.
7. Coleman SR. Structural fat grafting: More than a permanent filler. *Plast Reconstr Surg.* 2006;118:108–120.
8. Lewis CM. The current status of autologous fat grafting. *Aesthetic Plast Surg.* 1993;17:109–112.

9. Boschert MT, Beckert BW, Puckett CL, Concannon MJ. Analysis of lipocyte viability after liposuction. *Plast Reconstr Surg*. 2002;109:761–765.
10. Mikus JL, Koufman JA, Kilpatrick SE. Fate of liposuctioned and purified autologous fat injections in the canine vocal fold. *Laryngoscope* 1995;105:17–22.
11. Niechajev I, Sevcuk O. Long-term results of fat transplantation: Clinical and histologic studies. *Plast Reconstr Surg*. 1994;94:496–506.
12. Peer LA. Loss of weight and volume in human fat grafts. *Plast Reconstr Surg*. 1991;15:321–326.
13. Toledo LS, Mauad R. Fat injection: A 20-year revision. *Clin Plast Surg*. 2006;33:47–53.
14. Smahel J. Experimental implantation of adipose tissue fragments. *Br J Plast Surg*. 1989;42:207–211.
15. Björntorp P, Karlsson M, Pettersson P, Sypniekwska G. Differentiation and function of rat adipocyte precursor cells in primary culture. *J Lipid Res*. 1980;21:714–723.
16. Von Heimburg D, Kuberka M, Rendchen R, Hemmrich K, Rau G, Pallua N. Preadipocyte loaded collagen scaffolds with enlarged pore size for improved soft tissue engineering. *Int J Artif Organs* 2003;26:1064–1076.
17. Von Heimburg D, Zachariah S, Heschel I, et al. Human preadipocytes seeded on freeze-dried collagen scaffolds investigated in vitro and vivo. *Biomaterials* 2001;22:429–438.
18. Keck M, Haluza D, Burjak S, Eisenbock B, Kamolz LP, Frey M. Cultivation of keratinocytes and preadipocytes on a collagen-elastin scaffold (Matriderm): First results of an in vitro study. *Eur Surg*. 2009;41:189–193.
19. Rigotti G, Marchi A, Galiè M, et al. Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant: A healing process mediated by adipose-derived adult stem cells. *Plast Reconstr Surg*. 2007;119:1409–1422.
20. Serra-Renom JM, Muñoz-Olmo JL, Serra-Mestre JM. Fat grafting in postmastectomy breast reconstruction with expanders and prostheses in patients who have received radiotherapy: Formation of new subcutaneous tissue. *Plast Reconstr Surg*. 2010;125:12–18.
21. Keck M, Janke J, Ueberreiter K. Viability of preadipocytes in vitro: The influence of local anesthetics and pH. *Dermatol Surg*. 2009;35:1251–1257.
22. Körner A, Wabitsch M, Seidel B, et al. Adiponectin expression in humans is dependent on differentiation of adipocytes and down-regulated by humoral serum components of high molecular weight. *Biochem Biophys Res Commun*. 2005;337:540–550.
23. Coleman SR. Structural fat grafting: More than a permanent filler. *Plast Reconstr Surg*. 2006;118:108–120.
24. Smith P, Adams WP, Lipschitz AH, et al. Autologous human fat grafting: Effect of harvesting and preparation techniques on adipocyte graft survival. *Plast Reconstr Surg*. 2006;117:1836–1844.
25. Chang YS, Tseng SY, Tseng SH, Wu CL. Cytotoxicity of lidocaine or bupivacaine on corneal endothelial cells in a rabbit model. *Cornea* 2006;25:590–596.
26. Gerancher JC. Cauda equina syndrome following a single spinal administration of 5% hyperbaric lidocaine through a 25-gauge Whitacre needle. *Anesthesiology* 1997;87:687–689.
27. Lambert LA, Lambert DH, Strichartz GR. Irreversible conduction block in isolated nerve by high concentrations of local anesthetics. *Anesthesiology* 1994;80:1082–1093.
28. Pollock JE. Neurotoxicity of intrathecal local anesthetics and transient neurological symptoms. *Best Pract Res Clin Anaesthesiol*. 2003;17:471–484.
29. Sakaguchi M, Kuroda Y, Hirose M. The antiproliferative effect of lidocaine on human tongue cancer cells with inhibition of the activity of epidermal growth factor receptor. *Anesth Analg*. 2006;102:1103–1107.
30. Punke MA, Friederich P. Lipophilic and stereospecific interactions of amino-amide local anesthetics with human Kv1.1 channels. *Anesthesiology* 2008;109:895–904.
31. Werdehausen R, Fazeli S, Braun S, et al. Apoptosis induction by different local anaesthetics in a neuroblastoma cell line. *Br J Anaesth*. 2009;103:711–718.
32. Oertel R, Rahn R, Kirch W. Clinical pharmacokinetics of articaine. *Clin Pharmacokinet*. 1997;33:417–425.
33. Johnson ME. Neurotoxicity of lidocaine: Implications for spinal anesthesia and neuroprotection. *J Neurosurg Anesthesiol*. 2004;16:80–83.
34. Lirk P, Haller I, Myers RR, et al. Mitigation of direct neurotoxic effects of lidocaine and amitriptyline by inhibition of p38 mitogen-activated protein kinase in vitro and in vivo. *Anesthesiology* 2006;104:1266–1273.
35. Hogan QH. Pathophysiology of peripheral nerve injury during regional anesthesia. *Reg Anesth Pain Med*. 2008;33:435–441.
36. Adade AB, Chignell D, Vanderkooi G. Local anesthetics: A new class of partial inhibitors of mitochondrial ATPase. *J Bioenerg Biomembr*. 1984;16:353–363.
37. Haller I, Hausott B, Tomaselli B, et al. Neurotoxicity of lidocaine involves specific activation of the p38 mitogen-activated protein kinase, but not extracellular signal-regulated or c-jun N-terminal kinases, and is mediated by arachidonic acid metabolites. *Anesthesiology* 2006;105:1024–1033.
38. Lirk P, Haller I, Colvin HP, et al. In vitro, inhibition of mitogen-activated protein kinase pathways protects against bupivacaine- and ropivacaine-induced neurotoxicity. *Anesth Analg*. 2008;106:1456–1464.
39. Lirk P, Haller I, Colvin HP, et al. In vitro, lidocaine-induced axonal injury is prevented by peripheral inhibition of the p38 mitogen-activated protein kinase, but not by inhibiting caspase activity. *Anesth Analg*. 2007;105:1657–1064.
40. Sztark F, Ouhabi R, Dabadie P, Mazat JP. Effects of the local anesthetic bupivacaine on mitochondrial energy metabolism: Change from uncoupling to decoupling depending on the respiration state. *Biochem Mol Biol Int*. 1997;43:997–1003.
41. Tan Z, Dohi S, Chen J, Banno Y, Nozawa Y. Involvement of the mitogen-activated protein kinase family in tetracaine-induced PC12 cell death. *Anesthesiology* 2002;96:1191–1201.
42. Shoshani O, Berger J, Fodor L, et al. The effect of lidocaine and adrenaline on the viability of injected adipose tissue: An experimental study in nude mice. *J Drugs Dermatol*. 2005;44:311–316.
43. Beahm EK, Walton RL, Patrick CW Jr. Progress in adipose tissue construct development. *Clin Plast Surg*. 2003;30:547–558.
44. Patrick CW, Mikos AG, McIntire LV. *Frontiers in Tissue Engineering*. 1st ed. New York: Pergamon; 1998.
45. Coleman SR, Saboeiro A. Fat grafting to the breast revisited: Safety and efficacy. *Ann Plast Surg*. 2007;119:775–785.
46. Kimura Y, Ozeki M, Inamoto T, Tabata Y. Time course of de novo adipogenesis in matrigel by gelatin microspheres incorporating basic fibroblast growth factor. *Tissue Eng*. 2002;8:603–613.
47. Shetty S, Kusminski CM, Scherer PE. Adiponectin in health and disease: Evaluation of adiponectin-targeted drug development strategies. *Trends Pharmacol Sci*. 2009;30:234–239.
48. Mysore V, IADVL Dermatotomy Task Force. Tumescence liposuction: Standard guidelines of care. *Indian J Dermatol Venereol Leprol*. 2008;74(Suppl):S54–S60.
49. Holvoet P, De Keyzer D, Jacobs DR Jr. Oxidized LDL and the metabolic syndrome. *Future Lipidol*. 2008;6:637–649.